CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.

Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.

Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.